Argenx targets 2.5x more VYVGART patients by decade-end as Phase III empasiprubart MMN readout nears 4Q
Source: SeekingAlpha
2026-05-07 17:12:10 ET
More on argenx SE
- argenx SE (ARGX) Q1 2026 Earnings Call Transcript
- argenx SE: Excellent Company, Premium Valuation
- argenx SE 2025 Q4 - Results - Earnings Call Presentation
- argenx SE GAAP EPS of $5.52 beats by $0.31, revenue of $1.3B misses by $10M
- argenx SE Q1 2026 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Argenx targets 2.5x more VYVGART patients by decade-end as Phase III empasiprubart MMN readout nears 4Q
argenx SE
NASDAQ: ARGX
ARGX Trading
5.5% G/L:
$890.27 Last:
492,686 Volume:
$846.75 Open:
ARGX Latest News
ARGX Stock Data
$51,240,248,691
60,277,264
N/A
217
N/A
Biotechnology & Life Sciences
Healthcare
NL
Amsterdam
